Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication

ABSTARCT: Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame. Keywords: Poliovirus eradication, Immunodeficiency-associated vaccine-derived polioviruses, Oral poliovirus vaccine, Humoral immunodeficiency, Combined immunodeficiency, Primary immunodeficienc

Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination

Background Most poliovirus infections occur with no symptoms and this leads to the possibility of silent circulation, which complicates the confirmation of global goals to permanently end poliovirus transmission. Previous simple models based on hypothetical populations assumed perfect detection of symptomatic cases and suggested the need to observe no paralytic cases from wild polioviruses (WPVs) for approximately 3-4 years to achieve 95% confidence about eradication, but the complexities in real populations and the imperfect nature of surveillance require consideration. Methods We revisit the probability of undetected poliovirus circulation using a more comprehensive model that reflects the conditions in a number of places with different characteristics related to WPV transmission, and we model the actual environmental WPV detection that occurred in Israel in 2013. We consider the analogous potential for undetected transmission of circulating vaccine-derived polioviruses. The model explicitly accounts for the impact of different vaccination activities before and after the last detected case of paralytic polio, different levels of surveillance, variability in transmissibility and neurovirulence among serotypes, and the possibility of asymptomatic participation in transmission by previously-vaccinated or infected individuals. Results We find that prolonged circulation in the absence of cases and thus undetectable by case-based surveillance may occur if vaccination keeps population immunity close to but not over the threshold required for the interruption of transmission, as may occur in northwestern Nigeria for serotype 2 circulating vaccine-derived poliovirus in the event of insufficient tOPV use. Participation of IPV-vaccinated individuals in asymptomatic fecal-oral transmission may also contribute to extended transmission undetectable by case-based surveillance, as occurred in Israel. We also find that gaps or quality issues in surveillance could significantly reduce confidence about actual disruption. Maintaining high population immunity and high-quality surveillance for several years after the last detected polio cases will remain critical elements of the polio end game. Conclusions Countries will need to maintain vigilance in their surveillance for polioviruses and recognize that their risks of undetected circulation may differ as a function of their efforts to manage population immunity and to identify cases or circulating live polioviruses.Delft Institute of Applied MathematicsElectrical Engineering, Mathematics and Computer Scienc

The potential impact of expanding target age groups for polio immunization campaigns

Background Global efforts to eradicate wild polioviruses (WPVs) continue to face challenges due to uninterrupted endemic WPV transmission in three countries and importation-related outbreaks into previously polio-free countries. We explore the potential role of including older children and adults in supplemental immunization activities (SIAs) to more rapidly increase population immunity and prevent or stop transmission. Methods We use a differential equation-based dynamic poliovirus transmission model to analyze the epidemiological impact and vaccine resource implications of expanding target age groups in SIAs. We explore the use of older age groups in SIAs for three situations: alternative responses to the 2010 outbreak in Tajikistan, retrospective examination of elimination in two high-risk states in northern India, and prospective and retrospective strategies to accelerate elimination in endemic northwestern Nigeria. Our model recognizes the ability of individuals with waned mucosal immunity (i.e., immunity from a historical live poliovirus infection) to become re-infected and contribute to transmission to a limited extent. Results SIAs involving expanded age groups reduce overall caseloads, decrease transmission, and generally lead to a small reduction in the time to achieve WPV elimination. Analysis of preventive expanded age group SIAs in Tajikistan or prior to type-specific surges in incidence in high-risk areas of India and Nigeria showed the greatest potential benefits of expanded age groups. Analysis of expanded age group SIAs in outbreak situations or to accelerate the interruption of endemic transmission showed relatively less benefit, largely due to the circulation of WPV reaching individuals sooner or more effectively than the SIAs. The India and Nigeria results depend strongly on how well SIAs involving expanded age groups reach relatively isolated subpopulations that sustain clusters of susceptible children, which we assume play a key role in persistent endemic WPV transmission in these areas. Conclusions This study suggests the need to carefully consider the epidemiological situation in the context of decisions to use expanded age group SIAs. Subpopulations of susceptible individuals may independently sustain transmission, which will reduce the overall benefits associated with using expanded age group SIAs to increase population immunity to a sufficiently high level to stop transmission and reduce the incidence of paralytic casesDelft Institute of Applied MathematicsElectrical Engineering, Mathematics and Computer Scienc

Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial

Background: Polio eradication remains a challenge in Pakistan and the causes for the failure to eradicate poliomyelitis are complex. Undernutrition and micronutrient deficiencies, especially zinc deficiency, are major public health problems in Pakistan and could potentially affect the response to enteric vaccines, including oral poliovirus vaccine (OPV). Objective: To assess the impact of zinc supplementation among infants on immune response to oral poliovirus vaccine (OPV). Methods: A double-blind, randomized placebo-controlled trial was conducted in newborns (aged 0–14 days). Subjects were assigned to either receive 10 mg of zinc or placebo supplementation daily for 18 weeks. Both groups received OPV doses at birth, at 6 weeks, 10 weeks and 14 weeks. Data was collected on prior immunization status, diarrheal episodes, breastfeeding practices and anthropometric measurements at recruitment and at 6 and 18 weeks. Blood samples were similarly collected to determine the antibody response to OPV and for micronutrient analysis. Logistic regression was used to determine the relationship between seroconversion and zinc status. Results: Overall, 404 subjects were recruited. At recruitment, seropositivity was already high for poliovirus (PV) serotype 1 (zinc: 91.1%; control: 90.5%) and PV2 (90.0%; 92.7%), with lower estimates for PV3 (70.0%; 64.8%). By week 18, the proportion of subjects with measured zinc levels in the normal range (i.e. ≥60 μg/dL) was significantly greater in the intervention group compared to the control group (71.9%; 27.4%; p \u3c 0.001). No significant difference in seroconversion was demonstrated between the groups for PV1, PV2, or PV3. Conclusions: There was no effect of zinc supplementation on OPV immunogenicity. These conclusions were confirmed when restricting the analysis to those with measured higher zinc level

ICTV Virus Taxonomy Profile: Picornaviridae.

The family Picornaviridae comprises small non-enveloped viruses with RNA genomes of 6.7 to 10.1 kb, and contains >30 genera and >75 species. Most of the known picornaviruses infect mammals and birds, but some have also been detected in reptiles, amphibians and fish. Many picornaviruses are important human and veterinary pathogens and may cause diseases of the central nervous system, heart, liver, skin, gastrointestinal tract or upper respiratory tract. Most picornaviruses are transmitted by the faecal-oral or respiratory routes. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on the taxonomy of the Picornaviridae, which is available at www.ictv.global/report/picornaviridae

Echovirus infection causes rapid loss-of-function and cell death in human dendritic cells.

Contains fulltext : 51866.pdf (publisher's version ) (Closed access)Coxsackie B viruses (CVB) and Echoviruses (EV) form a single species; Human enterovirus B (HeV-B), within the genus Enterovirus. Although HeV-B infections are usually mild or asymptomatic, they can cause serious acute illnesses. In addition, HeV-B infections have been associated with chronic immune disorders, such as type 1 diabetes mellitus and chronic myocarditis/dilated cardiomyopathy. It has therefore been suggested that these viruses may trigger an autoimmune process. Here, we demonstrate that human dendritic cells (DCs), which play an essential role in orchestration of the immune response, are productively infected by EV, but not CVB strains, in vitro. Infection does not result in DC activation or the induction of antiviral immune responses. Instead, EV infection rapidly impedes Toll-like receptor-mediated production of cytokines and upregulation of maturation markers, and ultimately causes loss of DC viability. These results describe for the first time the effect of EV on the function and viability of human DCs and suggest that infection of DCs in vivo can impede regulation of immune responses

Search For Poliovirus Carriers Among People With Primary Immune Deficiency Diseases In The United States, Mexico, Brazil, And The United Kingdom

Objective: To estimate the rate of long-term poliovirus excretors in people known to have B-cell immune deficiency disorders. Methods: An active search for chronic excretors was conducted among 306 persons known to have immunoglobulin G (IgG) deficiency in the United States, Mexico, Brazil, and the United Kingdom, and 40 people with IgA deficiency in the United States. Written informed consent or assent was obtained from the participants or their legal guardians, and the studies were formally approved. Stool samples were collected from participants and cultured for polioviruses. Calculation of the confidence interval for the proportion of participants with persistent poliovirus excretion was based on the binomial distribution. Findings: No individuals with long-term excretion of polioviruses were identified. Most participants had received oral poliovirus vaccine (OPV) and almost all had been exposed to household contacts who had received OPV. Polioviruses of recent vaccine origin were transiently found in four individuals in Mexico and Brazil, where OPV is recommended for all children. Conclusion: Although chronic poliovirus excretion can occur in immunodeficient persons, it appears to be rare.82138Benyesh-Melnick, M., Melnick, J.L., Rawls, W.E., Wimberly, I., Oro, J.B., Ben-Porath, E., Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter (1967) American Journal of Epidemiology, 86, pp. 112-136Melnick, J.L., Benyesh-Melnick, M., Brennan, J.C., Studies on live poliovirus vaccines. Its neurotropic activity in monkeys and its increased neurovirulence after multiplication in vaccinated children (1959) JAMA, 171, pp. 1165-1172Gelfand, H.M., Potash, L., LeBlanc, D.R., Fox, J.P., Revised preliminary report on the Louisiana observations of the natural spread within families of living vaccine strains of poliovirus (1959) Live Poliovirus Vaccines: Papers Presented and Discussions Held at the First International Conference on Live Poliovirus Vaccines, , Special Publication No. 44. Washington (DC): Pan American Sanitary BureauFox, J.P., Gelfand, H.M., LeBlanc, D.R., Potash, L., Clemmer, D.I., LaPenta, D., The spread of vaccine strains of poliovirus in the household and in the community in southern Louisiana (1961) International Poliomyelitis Congress, Ed. Poliomyelitis: Papers and Discussions Presented at the Fifth International Poliomyelitis Conference, pp. 368-383. , Philadelphia: LippincottSutter, R.W., Cochi, S.L., Melnick, J.L., Live attenuated poliovirus vaccines (1999) Vaccines, 3rd Ed., pp. 364-408. , Plotkin SA, Orenstein WA, editors. Philadelphia: WB SaundersModlin, J.F., Coxsackieviruses, echoviruses, and newer enteroviruses (2000) Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 5th Ed., pp. 1904-1919. , Mandell GL, Bennett JE, Dolin R, editors. Philadelphia (PA): Churchill-LivingstoneWood, D.J., Sutter, R.W., Dowdle, W.R., Stopping poliovirus vaccination after eradication: Issues and challenges (2000) Bulletin of the World Health Organization, 78, pp. 347-357Kew, O.M., Sutter, R.W., Nottay, B.K., McDonough, M.J., Prevots, D.R., Quick, L., Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient (1998) Journal of Clinical Microbiology, 36, pp. 2893-2899Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis (2003) Journal of General Virology, 84, pp. 1215-1221John, T.J., Walker, D.H., Enterovirus infections, including poliomyelitis (1999) Tropical Infectious Diseases, Principles, Pathogens, and Practice, pp. 1123-1132. , Guerrant RL, Walker DH, Weller PF, editors. Philadelphia: Churchill LivingstoneMinor, P., Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies (2001) Developmental Biology, 105, pp. 75-80Minor, P.D., Ferguson, J.A., Icenogle, J.P., Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee (1986) Journal of General Virology, 67, pp. 693-706Dunn, G., Begg, N.T., Cammack, N., Minor, P.D., Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources (1990) Journal of Medical Virology, 32, pp. 92-95Sutter, R.W., Tangermann, R.H., Aylward, R.B., Cochi, S.L., Poliomyelitis eradication: Progress, challenges for the end game, and preparation for the post-eradication era (2001) Infectious Disease Clinics of North America, 15, pp. 41-64Conley, M.E., Notarangelo, L.D., Etzioni, A., Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and eSID (European Society for Immunodeficiencies) (1999) Clinical Immunology, 93, pp. 190-197(1997) Manual of the Virological Investigation of Poliomyelitis, , Geneva: World Health Organization. WHO document WHO/EPI/GEN/9701Liu, H.M., Zheng, D.P., Zhang, L.B., Oberste, M.S., Pallansch, M.A., Kew, O.M., Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China (2000) Journal of Virology, 74, pp. 11153-11161Savilahti, E., Klemola, T., Carlsson, B., Mellander, L., Stenvik, M., Hovi, T., Inadequacy of mucosal IgM antibodies in selective IgA deficiency excretion of attenuated polio viruses is prolonged (1988) Journal of Clinical Immunology, 8, pp. 89-94Triki, H., Barbouche, M.R., Bahri, O., Bejaoui, M., Dellagi, K., Community-acquired poliovirus infection in children with primary immunodeficiency in Tunisia (2003) Journal of Clinical Microbiology, 41, pp. 1203-1211Hammon, W.D., Coriell, L.L., Wehrle, P.F., Stokes, J., Evaluation of Red Cross gammaglobulin as a prophylactic agent for poliomyelitis. 4. Final report of results based on clinical diagnosis (1953) JAMA, 151, pp. 1272-1285Halliday, E., Winkelstein, J., Webster, A.D., Enteroviral infections in primary immunodeficiency (PID): A survey of morbidity and mortality (2003) The Journal of Infection, 46, pp. 1-8Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis (2003) Journal of General Virology, 84, pp. 1215-1221Cunningham-Rundles, C., Bodian, C., Common variable immunodeficiency: Clinical and immunological features of 248 patients (1999) Clinical Immunology, 92, pp. 34-48Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus (2002) Science, 296, pp. 356-359Halsey, N.A., Commentary: Poliomyelitis and unnecessary injections (2003) International Journal of Epidemiology, 32, pp. 278-279Halsey, N.A., Combination vaccines: Defining and addressing current safety concerns (2001) Clinical Infectious Diseases, 33 (SUPPL. 4), pp. S312-S31